Literature DB >> 19798642

"Cloud-like enhancement" is a magnetic resonance imaging abnormality specific to neuromyelitis optica.

Shoichi Ito1, Masahiro Mori, Takahiro Makino, Sei Hayakawa, Satoshi Kuwabara.   

Abstract

Neuromyelitis optica (NMO) is presumably mediated by an autoantibody against aquaporin-4 densely expressed at the blood-brain barrier. In 18 patients with NMO, brain magnetic resonance imaging (MRI) findings were systematically reviewed. Brain MRI abnormalities were found for 89% of the patients, and the most prominent feature was "cloud-like enhancement," multiple patchy enhancing lesions with blurred margin, found in 90% of the patients with positive contrast enhancement. In NMO, brain MRI abnormalities are frequent, and cloud-like enhancement appears to be an MRI finding specific to NMO, possibly caused by primary involvement of the blood-brain barrier by the autoantibodies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19798642     DOI: 10.1002/ana.21753

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  36 in total

Review 1.  Neuromyelitis optica spectrum disorders.

Authors:  Eoin P Flanagan; Brian G Weinshenker
Journal:  Curr Neurol Neurosci Rep       Date:  2014-09       Impact factor: 5.081

Review 2.  Brain MRI in neuromyelitis optica: what is its role?

Authors:  Wei Qiu; Allan G Kermode
Journal:  Curr Neurol Neurosci Rep       Date:  2011-12       Impact factor: 5.081

3.  Cerebrospinal fluid/serum gradient of IgG is associated with disability at acute attacks of neuromyelitis optica.

Authors:  Sung-Min Kim; Patrick Waters; Angela Vincent; Min Jin Go; Kyung Seok Park; Jung-Joon Sung; Kwang-Woo Lee
Journal:  J Neurol       Date:  2011-05-19       Impact factor: 4.849

4.  Racial differences in neuromyelitis optica spectrum disorder.

Authors:  Su-Hyun Kim; Maureen A Mealy; Michael Levy; Felix Schmidt; Klemens Ruprecht; Friedemann Paul; Marius Ringelstein; Orhan Aktas; Hans-Peter Hartung; Nasrin Asgari; Jessica Li Tsz-Ching; Sasitorn Siritho; Naraporn Prayoonwiwat; Hyun-June Shin; Jae-Won Hyun; Mira Han; Maria Isabel Leite; Jacqueline Palace; Ho Jin Kim
Journal:  Neurology       Date:  2018-10-26       Impact factor: 9.910

5.  Comparative clinical characteristics of neuromyelitis optica spectrum disorders with and without medulla oblongata lesions.

Authors:  Yanqiang Wang; Lei Zhang; Bingjun Zhang; Yongqiang Dai; Zhuang Kang; Ciyong Lu; Wei Qiu; Xueqiang Hu; Zhengqi Lu
Journal:  J Neurol       Date:  2014-03-09       Impact factor: 4.849

Review 6.  The current role of MRI in differentiating multiple sclerosis from its imaging mimics.

Authors:  Ruth Geraldes; Olga Ciccarelli; Frederik Barkhof; Nicola De Stefano; Christian Enzinger; Massimo Filippi; Monika Hofer; Friedemann Paul; Paolo Preziosa; Alex Rovira; Gabriele C DeLuca; Ludwig Kappos; Tarek Yousry; Franz Fazekas; Jette Frederiksen; Claudio Gasperini; Jaume Sastre-Garriga; Nikos Evangelou; Jacqueline Palace
Journal:  Nat Rev Neurol       Date:  2018-03-09       Impact factor: 42.937

7.  Brain MRI Findings in Pediatric-Onset Neuromyelitis Optica Spectrum Disorder: Challenges in Differentiation from Acute Disseminated Encephalomyelitis.

Authors:  E Bulut; J Karakaya; S Salama; M Levy; T A G M Huisman; I Izbudak
Journal:  AJNR Am J Neuroradiol       Date:  2019-03-07       Impact factor: 3.825

Review 8.  What do we know about brain contrast enhancement patterns in neuromyelitis optica?

Authors:  Yeliz Pekcevik; Gunes Orman; In Ho Lee; Maureen A Mealy; Michael Levy; Izlem Izbudak
Journal:  Clin Imaging       Date:  2015-07-26       Impact factor: 1.605

Review 9.  Differential diagnosis of white matter lesions: Nonvascular causes-Part II.

Authors:  S Weidauer; M Nichtweiss; E Hattingen
Journal:  Clin Neuroradiol       Date:  2014-02-12       Impact factor: 3.649

Review 10.  Conventional and advanced imaging in neuromyelitis optica.

Authors:  Y Barnett; I J Sutton; M Ghadiri; L Masters; R Zivadinov; M H Barnett
Journal:  AJNR Am J Neuroradiol       Date:  2013-06-13       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.